Medical Condition News

RSS

Gantenerumab appears to reduce brain amyloid levels in patients with AD

Although it is a small study and more clinical trials are needed, treatment with the medication gantenerumab appeared to result in a reduction in brain amyloid levels in patients with Alzheimer disease, according to a report published Online First by Archives of Neurology, one of the JAMA/Archives journals.

11 Oct 2011

Leg-crossers more likely to have good recovery after severe stroke

People who are able to cross their legs soon after having a severe stroke appear to be more likely to have a good recovery compared to people who can't cross their legs.

11 Oct 2011

Normal Htt protein regulates formation of cellular structures in mouse model of HD

Huntington disease is a devastating neurogenerative disorder that causes a progressive loss of functional capacity and reduced life span. It is an inherited condition caused by a mutant HTT gene. Although this has been known for many years, the functions of the normal Htt protein and the mechanisms by which the mutant protein generated from the mutant HTT gene causes disease are not well understood.

11 Oct 2011

Statins hold promise against traumatic brain injury

Older patients who happened to have been taking cholesterol-lowering statin drugs when admitted to the hospital with serious head injuries were 76 percent more likely to survive than those not taking the drugs, according to results of a Johns Hopkins study.

11 Oct 2011

Sirt1 protein enhances skeletal muscle insulin sensitivity in calorie-restricted mice

The number of individuals with type 2 diabetes is reaching epidemic proportions. One of the main risk factors for developing type 2 diabetes is resistance of cells in the body (particularly liver, fat, and skeletal muscle cells) to the effects of the hormone insulin.

11 Oct 2011

CXCL12 protein can inhibit metastasis of colon and melanoma cancers

Researchers at the Medical College of Wisconsin have shown that a protein can inhibit metastasis of colon and melanoma cancers. The findings are published in the October 10, 2011 issue of Proceedings of the National Academy of Sciences.

11 Oct 2011

New DCE-CT technique gives better clues to future cardiac events in heart patients

A new non-invasive technique for measuring how well the heart and blood vessels function in patients already suffering from coronary artery disease could, in a single test, identify which abnormally narrowed blood vessels are the most likely to lead to further cardiovascular complications.

11 Oct 2011

Takeda, Affymax announce data from multiple studies of peginesatide on anemia

Affymax, Inc. and Takeda Pharmaceuticals Global Research & Development Center, Inc., U.S., today announced data from multiple studies of peginesatide have been accepted for presentation at the American Society of Nephrology (ASN) Kidney Week 2011 taking place November 8-13, 2011 in Philadelphia, Pa.

11 Oct 2011

New information about effects of aging on the brain

Research by biologists at the University of York and Hull York Medical School has revealed important new information about the way the brain is affected by age.

11 Oct 2011

Villanova University establishes MacDonald Center for Obesity Prevention and Education

Obesity rates in the United States have reached epidemic proportions. According to the Centers for Disease Control and Prevention (CDC), two-thirds of adults are overweight or obese and 17 percent of children and teens (ages 2-19) are obese.

11 Oct 2011

Four-gene signature may predict patients at higher risk of OSCC recurrence

Oral Squamous Cell Carcinoma (OSCC) is responsible for nearly a quarter of all head and neck cancers. It is one of the leading causes of cancer death - largely due to the failure of current histological procedures in predicting the recurrence of the disease. New research published in BioMed Central's open access journal BMC Cancer shows that a four-gene signature may accurately predict which patients are at higher risk of OSCC recurrence.

11 Oct 2011

FDA clears Cardium's new Excellagen topical gel for diabetic foot ulcers

Cardium Therapeutics announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market and sell the Company's new Excellagen professional-use, sterile, syringe-based advanced wound care product for the management of diabetic foot ulcers and other dermal wounds.

11 Oct 2011

Case Western Reserve wins NCI grant to study genetic determinants of esophageal cancer

Case Western Reserve University School of Medicine and the Case Comprehensive Cancer Center are proud to announce the receipt of a highly competitive $5.4 million grant to study genetic determinants of Barrett's esophagus and esophageal adenocarcinoma.

11 Oct 2011

FDA to review Banner's Bexarotene ANDA for CTCL skin cancer treatment

Banner Pharmacaps Inc. has confirmed that its Abbreviated New Drug Application for Bexarotene 75 mg soft gelatin capsules, a generic version of Targretin, has been accepted for review by the US Food and Drug Administration.

11 Oct 2011

Rare and severe hypoglycemia could be genetic

The life-threatening condition depicts the fact that the body does not have enough energy to function. Scientists at the University of Cambridge say mutations in the AKT2 gene are to blame. Writing in the journal Science, they say there are already cancer drugs which target a similar process.

10 Oct 2011

Merck’s diabetes combo pill gets FDA nod

The U.S. Food and Drug Administration (FDA) has approved Merck & Co.’s Juvisync diabetes drug, a combination pill for type 2 diabetes. Juvisync combines two Merck drugs already on the market, 1) glucose-lowering Januvia (Sitagliptin) medication and 2) cholesterol-lowering Zocor (Simvastatin).

10 Oct 2011

Targacept commences AZD3480 Phase 2b study in Alzheimer’s disease

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today announced the initiation of a potential registration study of AZD3480 in mild to moderate Alzheimer's disease. The study is the subject of a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration.

10 Oct 2011

Cardium's Excellagen topical gel for diabetic foot ulcers receives FDA 510(k) clearance

Cardium Therapeutics announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market and sell the Company's new Excellagen™ professional-use, sterile, syringe-based advanced wound care product for the management of diabetic foot ulcers and other dermal wounds.

10 Oct 2011

AIM at Melanoma applauds bill banning children from using indoor tanning beds

AIM at Melanoma, the largest international foundation dedicated to melanoma research and patient advocacy, applauds Governor Jerry Brown's signing today of Senate Bill 746, which now bans children under 18 from using indoor tanning beds. Tanning beds have been linked to the rapid rise in melanoma rates among 15-39 year olds.

10 Oct 2011

Ford researchers develop series of in-car health and wellness apps, services

Researchers at Ford have developed a series of in-car health and wellness apps and services aimed at monitoring people with chronic illnesses or medical disorders so they can manage their condition while on the go.

From Medtronic 10 Oct 2011